

Alex Abizaid, MD, PhD. Director, Interventional Cardiology InCor, Sao Paulo University, Brazil

- ✓ Femural Closure
- ✓ Special Ballons
- ✓ Pacemaker wires
- Embolic Protection
- ✓ Leaflet Modification

#### ✓ Femural Closure

- ✓ Special Ballons
- ✓ Pacemaker wires
- ✓ Embolic Protection
- ✓ Leaflet Modification

# **Femural Closure Devices**

Prostar <sup>®</sup> XL	ProGlide®	MANTA™	PerQseal®	InSeal	
	ac the pa	S.C.	A de al		
Suture-based	Suture-based	Collagen-based	Patch-based	Membrane-based	
8.5–10 Fr	5–8 Fr	10-14 Fr (14 Fr system)	< 24 Fr	14–21 Fr	



**30-day Bleeding, Stenosis (dilation or surgery)** 

#### Shockwave M5





- ✓ Femural Closure
- ✓ Special Ballons
- ✓ Pacemaker wires
- Embolic Protection
- ✓ Leaflet Modification

#### **Clinical Need – Brain injury during left-sided heart procedures**

- Debris migration to brain during heart valve procedures leads to stroke (3-5%) and silent infarcts (up to 100%)
- Brain injury is among most feared complication for patients and leads to high cost for health care systems
- Silent infarcts are associated with 2-4-fold risk of future stroke, >3-fold risk of mortality, >2-fold risk of dementia



**Embolic Debris Migration** 

Picture: Illustration of aortic arch and hemodynamic flow with embolic debris.

#### New Cerebral Lesions in the brain



Picture: MR Images of cerebral lesions in the brain.

#### **Market – Competitive Landscape**

	<b>&gt;</b> Protembis	Scientific	Keystone Heart	Emboline		ICS	TransVerse **	Content of the second protocology	EnCompass
			*)		+			\$	
	ProtEmbo®	Sentinel™	TriGUARD <sub>3</sub> ™	Emboliner™	FLOWer™	Emblok™	Point-Guard <sup>™</sup>	CAPTIS™	F2 Filter <sup>™</sup>
Concept:	Deflect	Capture	Deflect	Capture	Capture	Capture	Deflect	Capture	Deflect
Status:	C€	CE FDA	CE	IDE	SIH	SIH	SIH	FIH	FIH
Pore size:	60 µm	140 μm	115x145 μm	150 μm	70 µm	125 µm	105 µm	115x150 μm	N/A
Access:	Left-radial	Right-radial	Femoral	Femoral	Femoral	Femoral	Femoral	Femoral	Femoral
Access size	6 Fr	6 Fr	8 Fr	10 Fr	12 Fr	11 Fr	10 Fr	16 Fr	N/A
Head vessels:	3/3	2/3	3/3	3/3	3/3	3/3	3/3	3/3	3/3
Coating:	Yes	No	Yes	Yes	N/A	No	No	N/A	N/A





**CEREBRAL PROTECTION SYSTEM** 

#### **Protection of the 3 vessels**



- ✓ Protects all 3 vessels to the brain
- ✓ Smallest filter pores 60 µm
- ✓ Quick implantation time (left radial access)
- ✓ 6 Minimal interference with the TAVR procedure
- ✓ Heparin coating for optimal blood compatibility





#### **IDE Trial – Adaptive Study Design**

CONFIDENTIAL



Adaptive study design with group sequential boundaries to assess outcomes at sequential interim analyses; First interim analysis at 250 patients with decision about conduct of trial based on predefined definitions of success or futility (by independent DSMB). After 250 patients further interim analyses each time 50 additional patients complete study up to maximum of 500 patients. **510(k) clearance based on superiority versus No Device Arm/ Hybrid Control Group**.

FDA = Food and Drug Administration (USA), IDE = Investigational Device Exemption, TAVR = Transcatheter Aortic Valve Replacement, MRI = Magnetic Resonance Imaging, DSMB = Data Safety & Monitoring Board.



# Emboliner



Conformable, cylindrical filter lines aorta, protecting all three cerebral vessels and descending aorta

Nitinol filter, 150 $\mu$ m pore size

Compatible with all TAVR systems



Expandable access port for TAVR delivery system Integrated 6 Fr lumen for pigtail Contralateral transfemoral access via integrated 9.5 Fr sheath



# Emboline

Full Body Embolic Protection

#### Initial Port Crossing



#### Advancement over Arch





#### **Debris Capture**

- SafePass 2 trial at 3 sites in New Zealand
  - Filters collected from SafePass 3 currently under analysis at CVPath Histopathology Laboratory
  - Emboliner captured >5x number of clinically relevant debris compared to Sentinel data



# **Protect Head-to-Head Study**



Randomization stratified by (a) site and (b) TAVR device type (Edwards or Medtronic) History of stroke patients randomized per device type throughout study cohort

**Primary Endpoint:** 30-day combined MACCE: all death, stroke\* and stage 3 AKI (non-inferiority) **Secondary Endpoints:** 

- 30-day stroke\* (non-inferiority)
- Number of particles captured >150 μm (superiority)

\*VARC2-defined

- ✓ Femural Closure
- ✓ Special Ballons
- ✓ Pacemaker wires
- ✓ Embolic Protection
- ✓ Leaflet Modification

# The Leaflex<sup>™</sup> Procedure



#### Basilica



#### ShortCut<sup>™</sup> Safe & Simple Coronary Access



- ✓ Certainly made procedures safer
- ✓ Higher chances of success
- ✓ Less bleeding
- ✓ Less Stroke
- ✓ Shorter hospital stay